{"id":"9mw2821","safety":{"commonSideEffects":[{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Immune-related pneumonitis"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Rash"},{"rate":null,"effect":"Hepatotoxicity"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"This drug belongs to the immune checkpoint inhibitor class and works by binding to programmed death ligand 1 (PD-L1) on tumor cells and immune cells, preventing the suppressive signal that tumors use to evade the immune system. By blocking this interaction, the drug restores T-cell activation and proliferation, enabling the body's immune system to recognize and attack cancer cells more effectively.","oneSentence":"9MW2821 is a monoclonal antibody targeting PD-L1 to enhance anti-tumor immune responses by blocking the interaction between PD-L1 and PD-1/B7-1.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T00:58:23.677Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Non-small cell lung cancer"},{"name":"Other solid tumors (under investigation)"}]},"trialDetails":[{"nctId":"NCT06649331","phase":"PHASE2","title":"Platform Study of ADC Rechallenge in ADC-treated Metastatic Breast Cancer","status":"RECRUITING","sponsor":"Fudan University","startDate":"2024-10-21","conditions":"Advanced Breast Cancer, Metastatic Breast Cancer, Triple Negative Breast Cancer (TNBC)","enrollment":160},{"nctId":"NCT06908928","phase":"PHASE1","title":"A Dose Randomization Study of Bulumtatug Fuvedotin in TNBC Patients Previously Treated With ADCs","status":"RECRUITING","sponsor":"Mabwell (Shanghai) Bioscience Co., Ltd.","startDate":"2025-08-11","conditions":"Triple Negative Breast Cancer","enrollment":52},{"nctId":"NCT07412171","phase":"PHASE2","title":"NECTAR Study: Neoadjuvant Toripalimab + 9MW2821 for Local UTUC","status":"NOT_YET_RECRUITING","sponsor":"Peking University Third Hospital","startDate":"2026-02","conditions":"Upper Tract Urothelial Carcinoma","enrollment":40},{"nctId":"NCT07314723","phase":"PHASE2","title":"9MW2821 Combined With Toripalimab in Perioperative Patients With Urothelial Cancer","status":"RECRUITING","sponsor":"Mabwell (Shanghai) Bioscience Co., Ltd.","startDate":"2025-08-01","conditions":"Urothelial Carcinoma","enrollment":90},{"nctId":"NCT07045311","phase":"PHASE2","title":"JS207 Combination Therapy in Triple-negative Breast Cancer","status":"RECRUITING","sponsor":"Shanghai Junshi Bioscience Co., Ltd.","startDate":"2025-09-17","conditions":"Triple-negative Breast Cancer","enrollment":80},{"nctId":"NCT06947226","phase":"PHASE1, PHASE2","title":"A Clinical Study of 9MW2821 Monotherapy or Combined With Other Anticancer Therapy in Advanced Solid Tumors","status":"NOT_YET_RECRUITING","sponsor":"Mabwell (Shanghai) Bioscience Co., Ltd.","startDate":"2025-04","conditions":"Solid Tumors","enrollment":188},{"nctId":"NCT06926998","phase":"PHASE1, PHASE2","title":"9MW2821 Combined With Other Antitumor Drugs in Patients With Advanced Gynecological Tumors","status":"NOT_YET_RECRUITING","sponsor":"Mabwell (Shanghai) Bioscience Co., Ltd.","startDate":"2025-04-15","conditions":"Gynecological Malignancies","enrollment":260},{"nctId":"NCT06196736","phase":"PHASE3","title":"A Study to Evaluate 9MW2821 Versus Chemotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Urothelial Cancer","status":"RECRUITING","sponsor":"Mabwell (Shanghai) Bioscience Co., Ltd.","startDate":"2023-12-29","conditions":"Advanced Urothelial Carcinoma","enrollment":432},{"nctId":"NCT06823427","phase":"PHASE2","title":"9MW2821 + Toripalimab vs 9MW2821 for 1st Line Locally Advanced or Metastatic Urothelial Carcinoma","status":"RECRUITING","sponsor":"Mabwell (Shanghai) Bioscience Co., Ltd.","startDate":"2025-01-17","conditions":"Urothelial Carcinoma, Urothelial Carcinoma Bladder, Urothelial Carcinoma Recurrent","enrollment":60},{"nctId":"NCT06492005","phase":"PHASE2","title":"A Clinical Study of 9MW2821 (and PD-1 Inhibitor) in Locally Advanced or Metastatic Triple-Negative Breast Cancer","status":"RECRUITING","sponsor":"Mabwell (Shanghai) Bioscience Co., Ltd.","startDate":"2024-07-26","conditions":"Triple-Negative Breast Cancer","enrollment":160},{"nctId":"NCT06692166","phase":"PHASE3","title":"A Study to Evaluate 9MW2821 Versus Treatment of Physician's Choice for Subjects With Recurrent or Metastatic Cervical Cancer","status":"RECRUITING","sponsor":"Mabwell (Shanghai) Bioscience Co., Ltd.","startDate":"2024-09-10","conditions":"Cervical Cancer","enrollment":420},{"nctId":"NCT05773937","phase":"PHASE1","title":"A Clinical Study of 9MW2821 in Advanced Malignant Solid Tumors","status":"RECRUITING","sponsor":"Mabwell (Shanghai) Bioscience Co., Ltd.","startDate":"2022-06-21","conditions":"Advanced Malignant Solid Tumors","enrollment":40},{"nctId":"NCT06592326","phase":"PHASE3","title":"9MW2821 in Combination With Toripalimab vs Standard Chemotherapy in Locally Advanced or Metastatic Urothelial Cancer","status":"RECRUITING","sponsor":"Mabwell (Shanghai) Bioscience Co., Ltd.","startDate":"2024-08-22","conditions":"Urothelial Carcinoma","enrollment":460},{"nctId":"NCT06079112","phase":"PHASE1, PHASE2","title":"9MW2821 Combined With Toripalimab Injection in Subjects With Local Advanced or Metastatic Urothelial Cancer","status":"RECRUITING","sponsor":"Mabwell (Shanghai) Bioscience Co., Ltd.","startDate":"2023-09-27","conditions":"Advanced Urothelial Carcinoma","enrollment":100},{"nctId":"NCT06551233","phase":"PHASE1","title":"Safety and Efficacy of 9MW2821 in the Treatment of High-risk Non-muscle-invasive Bladder Cancer (NMIBC)","status":"RECRUITING","sponsor":"The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School","startDate":"2024-04-22","conditions":"Bladder Cancer","enrollment":30},{"nctId":"NCT05216965","phase":"PHASE1, PHASE2","title":"A Clinical Study of 9MW2821 in Subjects With Advanced Malignant Solid Tumors","status":"UNKNOWN","sponsor":"Mabwell (Shanghai) Bioscience Co., Ltd.","startDate":"2022-06-11","conditions":"Solid Tumors","enrollment":208}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":4,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["9MW2821 injection"],"phase":"phase_3","status":"active","brandName":"9MW2821","genericName":"9MW2821","companyName":"Mabwell (Shanghai) Bioscience Co., Ltd.","companyId":"mabwell-shanghai-bioscience-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"9MW2821 is a monoclonal antibody targeting PD-L1 to enhance anti-tumor immune responses by blocking the interaction between PD-L1 and PD-1/B7-1. Used for Non-small cell lung cancer, Other solid tumors (under investigation).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}